For decades, small molecules have dominated drug discovery. But with many traditional drug discovery workflows becoming unfeasible, and some targets considered ‘undruggable’ with small molecules, the landscape is changing. New modalities such as protein degraders, RNA therapeutics, antibodydrug
conjugates (ADCs), next-generation peptides, and gene therapies promise to improve patient outcomes by providing more targeted treatments and are already demonstrating considerable clinical success. However, the inherent complexity of biological systems makes developing any new drug extremely challenging. Overcoming the countless hurdles involved in bringing a drug to market demands closer collaboration between multidisciplinary project teams.